The gates are closing.

Justice is coming.

Research questions effectiveness of drug

0 Comment(s)Print E-mail China Daily, May 20, 202

The latest clinical trial by Chinese researchers may disappoint doctors and patients worldwide hoping for the effectiveness of hydroxychloroquine, or HCQ, an anti-malaria and anti-inflammatory drug that has been used in several countries to treat COVID-19 cases.

The randomized controlled clinical trial conducted at 16 designated Chinese hospitals treating COVID-19 cases showed that the use of the drug did not accelerate the removal of the virus among mildly and moderately ill patients.

It was the world's first multicenter study of its kind to be released in a medical journal to assess the effectiveness of HCQ in treating novel coronavirus infection. A paper about the study was published on the website of the British Medical Journal on Friday.

"Compared with standard treatment, the use of HCQ for COVID-19 patients didn't help bring about a negative virus test result, nor did it shorten the term of the disease, and there exists a higher incidence rate of adverse drug reactions," said Xie Qing, director of the infectious disease department at Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, which led the multi-center research.

http://www.china.org.cn/china/2020-05/20/content_76066688.htm

China stepping up to fight HCQ effectiveness. Why now???